Cystic Fibrosis Epidemiology Forecast 2025-2034

Approximately 70,000 people worldwide are living with cystic fibrosis (CF), as per the American Lung Association. In the United States, around 30,000 individuals have the condition, and it is more commonly found among Caucasians. A 2022 study published in the Journal of Cystic Fibrosis provides a broader cystic fibrosis epidemiology forecast, estimating that about 162,428 people across 94 countries are affected by cystic fibrosis. However, researchers suggest that only around 65% of all cases have been officially diagnosed by doctors, indicating that many individuals with cystic fibrosis remain undiagnosed.

Cystic Fibrosis Epidemiology Forecast Report Coverage

The “Cystic Fibrosis Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of cystic fibrosis. It projects the future incidence and prevalence rates of cystic fibrosis cases across various populations. The study covers age, gender, and type as major determinants of the cystic fibrosis population. The report highlights patterns in the prevalence of cystic fibrosis over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on cystic fibrosis epidemiology in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Cystic Fibrosis Understanding: Disease Overview

Cystic fibrosis is a chronic genetic disease that primarily affects the lungs and digestive system. It causes the body to produce thick, sticky mucus that clogs the airways. The condition makes it hard for the affected patients to breathe and often leads to frequent lung infections. The mucus also impacts the pancreas, making it difficult to absorb nutrients from food.

Based on the severity of symptoms and the function of the CFTR protein, cystic fibrosis is classified into classic and atypical forms. Classic cystic fibrosis is the most severe form of CF, with patients having little to no functional CFTR protein. Cystic fibrosis is inherited from both parents and is more prevalent among Caucasians. Common symptoms include persistent coughing, wheezing, lung infections, and poor weight gain, among others.

Cystic Fibrosis Epidemiology Perspective

The cystic fibrosis epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for cystic fibrosis epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for cystic fibrosis and their trends. The cystic fibrosis detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Around 70,000 people worldwide are living with cystic fibrosis, according to the American Lung Association. Further, approximately 30,000 individuals are living with cystic fibrosis in the United States.
• A 2022 study published in the Journal of Cystic Fibrosis estimated that about 162,428 people across 94 countries are affected by cystic fibrosis.
• Approximately 1 in 4,000 babies in the United States are born with cystic fibrosis, with the condition more prevalent among individuals with Northern European heritage, as per a 2020 review.
• A pilot study published in BMC Medical Genetics (2020) reported an exceptionally high carrier frequency of CFTR mutations at a center in North India, with 1 in 22 individuals (4.5%) found to be carriers.

Age-Based Cystic Fibrosis Epidemiology Insights

Nearly 75% of individuals with cystic fibrosis are diagnosed before turning 2 years old. The Cystic Fibrosis Foundation reports that over 50% of people with cystic fibrosis are adults, which means that less than 20,000 children are affected by the condition in the United States. The global estimates indicate that about 55,000 children have been diagnosed with cystic fibrosis.

Gender-Based Cystic Fibrosis Epidemiology Insights

Men make up slightly more than 50% of all cystic fibrosis cases and generally experience better health outcomes compared to women, particularly during childhood and adolescence. Studies show that until around age 20, males tend to have better lung function, lower rates of lung infections, and a slower decline in respiratory health. After this age, survival rates between men and women become more similar.

Country-wise Cystic Fibrosis Epidemiology Segment

The cystic fibrosis epidemiology data and findings from the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of cystic fibrosis varies between countries, owing to differences in factors such as genetic predisposition, newborn screening programs, healthcare access, and diagnostic practices. Cystic fibrosis affects about 11,148 people in the United Kingdom and 9,259 people in England, as per the recent estimates from the Cystic Fibrosis Trust.

Cystic Fibrosis: Treatment Overview

Cystic fibrosis therapeutics such as mucus-thinning drugs, bronchodilators, and antibiotics are commonly used to clear the airways and reduce lung infections. CFTR modulators, a newer class of drugs, are being increasingly preferred as they target the underlying genetic defect to improve lung function and reduce symptoms. Airway clearance techniques, such as chest physiotherapy and specialized breathing devices, are used to remove thick mucus from the lungs. In severe cases, oxygen therapy or a lung transplant may be considered as a treatment option.

Key Questions Answered

• What are the key findings of cystic fibrosis epidemiology in the 8 major markets?
• What will be the total number of patients with cystic fibrosis across the 8 major markets during the forecast period?
• What was the country-wise cystic fibrosis epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of cystic fibrosis patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of cystic fibrosis during the forecast period of 2025-2034?
• What are the currently available treatments in the cystic fibrosis market?
• What are the disease risks, signs, symptoms, and unmet needs of cystic fibrosis?

Scope of the Cystic Fibrosis Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of cystic fibrosis based on several factors.
• Cystic Fibrosis Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The cystic fibrosis report helps to identify the patient population and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

This product will be delivered within 3-5 business days.